A vasoactive intestinal peptide test measures VIP, a neuropeptide that relaxes smooth muscle and stimulates secretion of water and electrolytes into the intestine. The plasma test is used mainly when a person has persistent, high-volume watery diarrhea that continues during fasting and is accompanied by low potassium, dehydration, metabolic acidosis, or a suspected neuroendocrine tumor. Markedly high VIP can support VIPoma, a rare functional tumor usually arising in the pancreas, but the result is not a general screen for cancer or for ordinary diarrhea. Collection is technically demanding because VIP is unstable; EDTA plasma generally must be separated and frozen immediately. Mild elevations can be nonspecific, and a normal result does not exclude all malignancy or every episode of intermittent hormone secretion. Interpretation depends on stool volume, fasting behavior, electrolytes, kidney function, medications and laxatives, assay method, imaging, and the overall clinical syndrome. Severe secretory diarrhea can cause life-threatening potassium and fluid losses, so stabilization with intravenous fluids and electrolyte replacement takes priority over waiting for a send-out hormone result.
- VIP testing is most appropriate for chronic, high-volume secretory diarrhea, not a brief infectious illness or typical irritable bowel syndrome.
- VIPoma classically causes watery diarrhea, hypokalemia, and low gastric acid, known as WDHA syndrome.
- A frozen EDTA plasma sample collected and processed correctly is essential because VIP degrades rapidly.
- High VIP supports a secreting tumor only when the clinical pattern fits; method-specific reference ranges and repeat confirmation matter.
- Severe weakness, fainting, confusion, very low potassium, reduced urination, or inability to keep fluids down requires urgent care.
Table of Contents
- What VIP Does
- Why the VIP Test Is Ordered
- Preparation and Specimen Collection
- Normal Range and Result Interpretation
- High VIP and VIPoma Syndrome
- Other Causes of Watery Diarrhea
- Diagnosis, Imaging, and Treatment
- Limitations, Monitoring, and Safety
What VIP Does
Vasoactive intestinal peptide is a 28-amino-acid neuropeptide found throughout the central and peripheral nervous systems. It is especially abundant in enteric nerves of the gastrointestinal tract but is also present in the respiratory and urogenital systems, pancreas, thyroid, adrenal tissue, and other organs.
VIP acts through G-protein-coupled receptors, principally VPAC1 and VPAC2. Its major physiological effects include:
- Stimulating intestinal chloride, bicarbonate, potassium, and water secretion
- Relaxing gastrointestinal, vascular, and bronchial smooth muscle
- Dilating blood vessels
- Reducing gastric acid secretion
- Modifying pancreatic hormone and enzyme release
- Influencing immune and circadian signaling
In normal physiology, VIP is released locally from nerves and acts over a short distance. Circulating concentrations are low. A tumor that releases large amounts into the bloodstream overwhelms normal local regulation and turns the intestine into a continuously secreting organ.
The resulting diarrhea is secretory. Chloride and water move into the intestinal lumen, and potassium and bicarbonate are lost in stool. The diarrhea persists even when the person stops eating because it is driven by hormone signaling rather than unabsorbed food. Stool volumes can reach several liters per day.
Loss of potassium causes weakness, cramps, abnormal heart rhythms, ileus, and in severe cases paralysis. Bicarbonate loss produces a normal-anion-gap metabolic acidosis. Sodium and water loss cause thirst, low blood pressure, kidney injury, and shock. The syndrome can also cause high calcium, flushing, glucose intolerance, and weight loss.
VIP is not the same as gastric inhibitory peptide, now called glucose-dependent insulinotropic peptide. It is also not a routine pancreatic enzyme or a marker of exocrine pancreatic reserve. A high VIP value reflects excess circulating peptide activity, not simply “pancreatic inflammation.”
Most VIP-producing tumors in adults are pancreatic neuroendocrine tumors. In children, VIP secretion can occur with neurogenic tumors such as neuroblastoma or ganglioneuroma. Rare nonpancreatic sources and other tumors have been reported.
Why the VIP Test Is Ordered
The test is ordered when the diarrhea pattern suggests an endocrine secretory process. Chronic diarrhea is common, but VIPoma is rare, so selecting the right patients is essential.
Features that increase the usefulness of VIP testing include:
- Large-volume watery stools, often more than 700 mL per day and sometimes several liters
- Diarrhea that persists during a supervised fast or overnight
- Low potassium that is difficult to correct
- Metabolic acidosis from bicarbonate loss
- Dehydration, low blood pressure, or kidney injury
- Weight loss despite adequate intake
- Flushing or glucose intolerance in some patients
- A pancreatic or abdominal mass
- A child with a neuroblastic tumor and refractory watery diarrhea
A laboratory source notes that a VIP-producing tumor is unlikely when 24-hour stool volume is below 700 mL. That is not an absolute exclusion, but it illustrates the typical high-volume phenotype.
The test is usually inappropriate for:
- Acute gastroenteritis lasting a few days
- Diarrhea clearly linked to antibiotics or a known medication
- Typical irritable bowel syndrome without nocturnal or fasting diarrhea
- Mild loose stools without electrolyte loss
- Cancer screening in an asymptomatic person
- Routine evaluation of diabetes or pancreatitis
Before ordering VIP, clinicians often classify diarrhea as watery, fatty, or inflammatory and determine whether watery diarrhea is osmotic or secretory. Osmotic diarrhea improves with fasting and has a high stool osmotic gap. Secretory diarrhea continues during fasting and usually has a low osmotic gap because measured electrolytes account for most stool osmolality.
A 24-hour stool collection can quantify volume and weight. Stool sodium and potassium permit calculation of the osmotic gap:
Stool osmotic gap = 290 − 2 × (stool sodium + stool potassium)
A low gap supports secretory diarrhea, although collection errors and mixed mechanisms are common. The VIP result should be interpreted with this physiology rather than ordered from stool frequency alone.
Medication and laxative review is critical. Stimulant or osmotic laxatives, magnesium-containing products, sugar alcohols, colchicine, metformin, antibiotics, and many other agents can cause chronic diarrhea. Surreptitious laxative use can mimic an endocrine syndrome and should be approached nonjudgmentally.
Preparation and Specimen Collection
VIP is unstable, and poor handling can create a falsely low result. One current reference laboratory requires plasma collected in a lavender-top EDTA tube, prompt centrifugation, transfer to a plastic vial, and immediate freezing. Gross hemolysis or lipemia may be rejected.
The exact test directory should be checked before collection. Some laboratories provide a dedicated kit or require a protease inhibitor. Specimens from different methods are not interchangeable.
Fasting is often recommended to standardize collection and document that diarrhea continues without food, although the laboratory’s written instructions take priority. The patient should not attempt a prolonged fast while severely dehydrated or hypokalemic. Inpatient observation may be safer when stool losses are high.
Record:
- Duration and approximate daily stool volume
- Whether diarrhea continues overnight and during fasting
- Recent oral and intravenous fluids
- Potassium, bicarbonate, magnesium, calcium, creatinine, and glucose
- All medicines, supplements, and laxatives
- Prior bowel or pancreatic surgery
- Known neuroendocrine tumor or hereditary syndrome
- Timing of somatostatin analog treatment
Octreotide and related medicines can rapidly reduce VIP secretion and diarrhea. A sample collected after treatment may be lower than the untreated level. Therapy should not be withheld in an unstable patient merely to improve diagnostic yield.
The blood draw is not the only important specimen. Stool cultures, parasite testing, Clostridioides difficile testing, fecal inflammatory markers, fecal fat, laxative screens, or electrolyte measurements may be needed depending on the history. Celiac serology, thyroid tests, cortisol, gastrin, calcitonin, 5-HIAA, or other endocrine tests are selected when their syndromes are plausible.
Because VIP testing may take several days, treatment decisions for dehydration and electrolyte loss are based on immediate chemistry. Potassium replacement requires monitoring because rapid or excessive replacement can be dangerous, especially with kidney dysfunction.
If the result is unexpected, the laboratory should confirm that the sample remained frozen and identify the assay’s sensitivity, reference interval, and potential antibody interference. Repeating a properly handled sample during active diarrhea can be more informative than interpreting a borderline value from uncertain conditions.
Normal Range and Result Interpretation
VIP is commonly reported in picograms per milliliter. One current enzyme-linked immunosorbent assay lists a reference value below 86 pg/mL. Other laboratories use different cutoffs, including lower upper limits, because antibodies, calibrators, extraction, and assay design differ.
The result should be interpreted in context:
| Result and clinical pattern | General interpretation |
|---|---|
| Normal VIP with low-volume or intermittent diarrhea | VIPoma is unlikely; investigate more common causes |
| Normal VIP during severe secretory diarrhea | Review specimen handling, treatment timing, assay sensitivity, and alternative secretagogues |
| Mild elevation without high-volume fasting diarrhea | Nonspecific; repeat and assess kidney function, assay interference, and clinical fit |
| Marked repeated elevation with WDHA physiology | Strongly supports a VIP-secreting tumor and warrants localization |
| Falling VIP after treatment with improved stool output | Supports biochemical response if measured by the same method |
There is no single universal diagnostic cutoff. Many descriptions of VIPoma use concentrations above approximately 200 pg/mL in the correct syndrome, but assays differ, and some confirmed cases have lower or intermittent values. The laboratory’s method-specific interpretation and the magnitude relative to its upper limit are more useful than an internet threshold.
A high result is not absolute evidence of cancer. It supports hormone hypersecretion, which may come from a benign-appearing or malignant neuroendocrine tumor. Malignancy is defined by invasion, metastasis, grade, and behavior—not by the VIP concentration.
A normal value does not rule out every malignancy. Most pancreatic cancers do not secrete VIP, and nonfunctional pancreatic neuroendocrine tumors may have normal levels. The test should never be used as a broad cancer screen.
A mild elevation may occur in healthy controls, kidney dysfunction, inflammatory bowel disease, short bowel states, or other conditions depending on the assay. Heterophile antibodies can cause false immunoassay signals. The result is persuasive only when it reproduces and matches secretory physiology.
Stool output often provides useful biological context. A person passing a few loose stools daily without hypokalemia has a very different pretest probability from someone producing liters of watery stool despite fasting.
High VIP and VIPoma Syndrome
VIPoma is a rare functional neuroendocrine tumor. In adults, most arise in the pancreas, often in the body or tail, and may be large by diagnosis because early symptoms are attributed to common gastrointestinal disease. Some have already spread to the liver or lymph nodes when found.
The classic syndrome is abbreviated WDHA:
- Watery diarrhea
- Hypokalemia
- Achlorhydria or hypochlorhydria
It is also called pancreatic cholera or Verner-Morrison syndrome. Not every patient has documented low gastric acid, so the combination of secretory diarrhea and potassium loss is often the practical clue.
Watery diarrhea
VIP activates intestinal cyclic AMP pathways, driving chloride and water secretion. The diarrhea is typically painless, persistent, and unaffected by fasting. Stool may be tea-colored and odorless, but appearance is not diagnostic. Volumes can be massive enough to require continuous intravenous fluid replacement.
Electrolyte and acid-base changes
Potassium loss is often profound. Bicarbonate loss causes metabolic acidosis rather than the alkalosis seen with vomiting. Magnesium can be low, making potassium harder to correct. Dehydration reduces kidney perfusion and can cause acute kidney injury.
Hypercalcemia may occur from dehydration, bone effects, coexisting hyperparathyroidism in multiple endocrine neoplasia type 1, or other mechanisms. Glucose intolerance can result from altered pancreatic hormone release and stress.
Other symptoms
Flushing can occur because VIP dilates blood vessels. Weight loss, weakness, abdominal pain, nausea, bloating, and gallbladder enlargement have been reported. The severity fluctuates with hormone secretion and treatment.
In children, a VIP-secreting neuroblastoma or ganglioneuroma can produce chronic diarrhea, growth failure, dehydration, and hypokalemia. The tumor may arise in the adrenal or sympathetic chain rather than pancreas. Pediatric evaluation requires oncology and endocrinology expertise.
VIPoma can be associated with multiple endocrine neoplasia type 1, although most cases are sporadic. A young patient, multiple pancreatic tumors, family history, hyperparathyroidism, or pituitary disease should prompt genetic counseling.
The concentration may correlate imperfectly with symptoms. Receptor responsiveness, tumor secretion pattern, kidney clearance, stool intake, and treatment all contribute. Clinical stabilization should be guided by losses and chemistry rather than waiting for a particular VIP number.
Other Causes of Watery Diarrhea
Even dramatic diarrhea is more likely to have a cause other than VIPoma. A structured differential prevents unnecessary tumor imaging and missed treatable disease.
Medication and laxative effects
Common culprits include metformin, magnesium, antibiotics, colchicine, mycophenolate, olmesartan, proton pump inhibitors, selective serotonin reuptake inhibitors, nonsteroidal anti-inflammatory drugs, and chemotherapy. Stimulant laxatives and osmotic agents can be hidden in supplements, teas, or bowel products.
Infection
Persistent infection can result from C. difficile, Giardia, Cryptosporidium, Cyclospora, HIV-related pathogens, or travel exposures. Stool testing is guided by duration and risk.
Inflammatory and microscopic colitis
Inflammatory bowel disease may cause blood, pain, fever, anemia, and elevated fecal calprotectin, but presentations vary. Microscopic colitis often causes chronic watery nocturnal diarrhea with a normal-looking colon; diagnosis requires biopsies.
Malabsorption and bile-acid diarrhea
Celiac disease, pancreatic insufficiency, short bowel, small intestinal bacterial overgrowth, and bile-acid malabsorption can cause watery or fatty stools. Prior gallbladder or intestinal surgery provides important clues.
Other endocrine and neuroendocrine syndromes
- Gastrinoma can cause acid hypersecretion and diarrhea.
- Carcinoid syndrome can cause diarrhea and flushing, usually with elevated 5-HIAA.
- Medullary thyroid carcinoma can secrete calcitonin and other peptides.
- Hyperthyroidism increases motility.
- Adrenal insufficiency can cause gastrointestinal symptoms, low sodium, and high potassium rather than the typical VIPoma pattern.
- Somatostatinoma can cause diabetes, gallstones, steatorrhea, and weight loss.
A somatostatin blood test or another hormone test is selected only when its clinical syndrome is present. Broad panels create incidental abnormalities.
Congenital secretory diarrheas
In infants and children, chloride or sodium transport disorders, epithelial defects, and other genetic diseases can cause life-threatening watery diarrhea. Age at onset and stool electrolyte composition guide specialized genetic evaluation.
If stool volume falls substantially during fasting, an osmotic cause becomes more likely. If diarrhea continues, clinicians consider secretory, inflammatory, or motility mechanisms. This distinction is useful but not absolute because mixed disorders occur.
Diagnosis, Imaging, and Treatment
Diagnosis begins with stabilization and confirmation of secretory diarrhea. A typical workup includes:
- Measure stool volume or weight and document fasting persistence.
- Check sodium, potassium, chloride, bicarbonate, magnesium, calcium, creatinine, glucose, and acid-base status.
- Review medicines, supplements, and laxatives.
- Exclude common infectious, inflammatory, and malabsorptive causes.
- Obtain a correctly handled plasma VIP level during active symptoms.
- Repeat or confirm a borderline result before extensive localization.
- Image for a neuroendocrine tumor when biochemical and clinical evidence align.
Contrast-enhanced CT or MRI can identify a pancreatic mass and liver metastases. Endoscopic ultrasound is useful for selected pancreatic lesions. Somatostatin-receptor PET imaging can show receptor-positive disease throughout the body and help determine eligibility for receptor-targeted treatment. In children, imaging follows the likely neuroblastic tumor location.
Tissue diagnosis establishes neuroendocrine differentiation and grade. Pathology may use synaptophysin, chromogranin A, INSM1, VIP staining, mitotic count, and Ki-67 index. Tumor grade and stage influence prognosis and treatment.
Immediate treatment
The first priority is replacing water and electrolytes. Intravenous saline, potassium, bicarbonate when indicated, and magnesium may be needed. Kidney function and electrocardiography guide safe replacement. Severe losses often require intensive monitoring.
Octreotide or another somatostatin analog can reduce VIP release and intestinal secretion rapidly. Some patients respond dramatically; others require dose adjustment or additional antidiarrheal support. High doses can affect glucose, gallbladder function, and digestion.
Tumor-directed treatment
Surgical resection offers the best chance of cure for localized disease. Procedures range from enucleation or distal pancreatectomy to more extensive surgery depending on location and vascular involvement.
For metastatic or unresectable disease, options may include long-acting somatostatin analogs, targeted therapy, peptide receptor radionuclide therapy, liver-directed embolization or ablation, chemotherapy, and cytoreductive surgery. Treatment is individualized by a multidisciplinary neuroendocrine tumor team.
Nutrition is part of treatment. Chronic diarrhea causes weight and muscle loss, vitamin deficiency, and reduced oral intake. Dietitians help replace calories, protein, salt, potassium, and micronutrients while avoiding advice that worsens dehydration. Oral rehydration solutions can be useful in stable patients but may be insufficient for very high losses.
Limitations, Monitoring, and Safety
VIP testing has several limitations:
- The hormone is unstable and requires immediate frozen processing.
- Assays are method-dependent and serial values may not be interchangeable.
- Sensitivity may be insufficient for intermittent or low-level secretion.
- Mild elevations are not specific.
- Heterophile antibodies can interfere with immunoassays.
- Treatment before collection can lower the result.
- A normal value does not exclude a non-VIP-secreting tumor.
A result should not be interpreted as absolute proof of malignant disease. Conversely, the absence of elevation does not rule out cancer. The test answers a narrower question: is excess circulating VIP likely to explain this secretory diarrhea syndrome?
For monitoring, the most useful endpoints are stool volume, potassium and bicarbonate requirements, hydration, weight, kidney function, symptoms, imaging, and VIP concentration when it was clearly elevated at baseline. The same laboratory method should be used where possible.
A rising VIP without worsening symptoms or imaging should be repeated under comparable conditions. A falling value with clinical improvement supports response, but tumor growth can occasionally diverge from hormone secretion. Imaging remains necessary.
Patients with a hereditary syndrome require additional surveillance. In MEN1, this may include calcium and parathyroid hormone, pituitary assessment, and imaging for multiple pancreatic or duodenal tumors. Family members should not be screened with VIP alone; genetic counseling determines the appropriate pathway.
Emergency warning signs include fainting, confusion, severe weakness, palpitations, minimal urination, very dry mouth, inability to drink, blood pressure collapse, or persistent vomiting. Hypokalemia can cause dangerous arrhythmias even before a patient feels critically ill. Emergency services are appropriate when severe symptoms develop.
Do not self-treat suspected VIPoma with large amounts of potassium supplements. Oral potassium can injure the gastrointestinal tract and become dangerous if kidney function changes. Replacement should be based on measured levels and medical supervision.
The VIP test is most valuable when it is the final biochemical piece in a coherent syndrome: liters of watery stool despite fasting, low potassium and bicarbonate, dehydration, and a compatible tumor. In ordinary chronic diarrhea without that pattern, careful medication review, stool evaluation, colon biopsies when needed, and common gastrointestinal diagnoses are far more likely to provide the answer.
References
- VIP – Overview: Vasoactive Intestinal Polypeptide, Plasma 2026 (Laboratory test information)
- Neuroendocrine Tumors | Choose the Right Test 2026 (Laboratory guidance)
- Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy 2025 (Case report)
- Nutritional Management of Functioning GEP-NENs 2025 (Review)
- Chronic diarrhea related to neuroblastoma: the important role of vasoactive intestinal peptide in pathogenesis and diagnosis 2025 (Study)
Disclaimer
This article is general education and cannot diagnose VIPoma or determine the cause of chronic diarrhea. VIP results require interpretation with stool volume, electrolytes, fasting behavior, specimen handling, medications, imaging, and clinical findings. Severe dehydration, confusion, fainting, reduced urination, or suspected dangerous hypokalemia requires urgent medical care.
